A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Evolocumab (AMG 145) on LDL-C in Subjects With Type 2 Diabetes Mellitus and Hypercholesterolemia/Mixed Dyslipidemia
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Evolocumab (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Amgen
- 09 Aug 2017 Planned End Date changed from 31 Jul 2017 to 5 Sep 2017.
- 09 Aug 2017 Planned primary completion date changed from 31 Jul 2017 to 5 Sep 2017.
- 10 Jun 2017 Biomarkers information updated